Nasal allergies and beyond: a clinical review of the pharmacology, efficacy, and safety of mometasone furoate.
Mometasone furoate nasal spray (MFNS; Nasonex, Schering-Plough Corporation, Kenilworth, NJ, USA) is an effective and well-tolerated intranasal corticosteroid approved for the prophylactic treatment of seasonal allergic rhinitis, and the treatment of perennial allergic rhinitis. MFNS is a potent molecule with a rapid onset of action and excellent safety and efficacy profiles. Having recently received approval for the treatment of nasal polyposis, data indicate that MFNS may also be effective in rhinosinusitis.
van Drunen
C
C
Department of Otorhinolaryngology, Academic Medical Center, University of Amsterdam, The Netherlands.
Meltzer
E O
EO
Bachert
C
C
Bousquet
J
J
Fokkens
W J
WJ
D018926:Anti-Allergic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D000068656:Mometasone Furoate; D011244:Pregnadienediols / Q000009:adverse effects / Q000627:therapeutic use*; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*; D016896:Treatment Outcome
D018926:Anti-Allergic Agents; D011244:Pregnadienediols; D000068656:Mometasone Furoate